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Abstract: Thrombosis is the main outcome of many cardiovascular diseases. Current 
treatments to prevent thrombotic events involve the long-term use of antiplatelet drugs. 
However, this therapy has several limitations, thereby justifying the development of new 
drugs. A series of N-oxide derivatives (furoxan and benzofuroxan) were synthesized and 
characterized as potential antiplatelet/antithrombotic compounds. All compounds (3a,b, 
4a,b, 8a,b, 9a,b, 13a,b and 14a,b) inhibited platelet aggregation induced by adenosine-5-
diphosphate, collagen, and arachidonic acid. All compounds protected mice from 
pulmonary thromboembolism induced by a mixture of collagen and epinephrine; however, 
benzofuroxan derivatives (13a,b and 14a,b) were the most active compounds, reducing 
thromboembolic events by up to 80%. N-oxide derivative 14a did not induce genotoxicity  
in vivo. In conclusion, 14a has emerged as a new antiplatelet/antithrombotic prototype 
useful for the prevention of atherothrombotic events. 
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1. Introduction 
Cardiovascular diseases (CVD) are the main cause of death worldwide. In 2012, approximately 17.5 
million people died from CVD, which represents 31% of all deaths worldwide in that year. Estimative 
data suggest that deaths by CVD could reach 25 million in 2030 [1], with thrombosis being one of the 
primary outcomes [2]. 
Currently, antiplatelet drugs (APDs) represent one of the major classes of antithrombotic drugs. In 
2013, APD sales reached 9.5 billion dollars, accounting for 40.4% of all antithrombotic drugs [3]. 
APDs target key pathways on the platelet surface, namely adenosine-5-diphosphate (ADP)-mediated 
signaling, thromboxane A2 synthesis, and integrin αIIbβ3. In long-term therapy, APDs prevent clot 
formation and vaso-occlusion [4]. Despite the clinical advantages of APD therapy, recurrent vascular 
events still occur in 10%–20% of all patients under treatment [5]. In addition, 5%–40% of coronary 
patients treated with APDs do not show a protective response [6].  
Current antiplatelet/antithrombotic therapies have several limitations, which include blocking a 
single pathway of platelet aggregation, increase in bleeding time, weak inhibition of platelet 
aggregation, high variability in the patients’ responses, and slow onset of action [7]. Recently, the term 
“resistance” emerged in the literature to describe the limited efficacy of drugs, such as acetylsalicylic 
acid (ASA) and clopidogrel. The percentage of drug-resistant individuals ranged from 4%–30% among 
the patients [8]. This resistance is related to factors such as increased activity of alternative pathways 
in platelets, drug-drug interactions, pharmacogenetic factors, and poor adherence to the therapy [8,9].  
Therefore, the discovery of safe and effective compounds to prevent thromboembolic events is a 
milestone that still needs to be overcome in the current therapy. N-oxide derivatives (e.g., furoxan and 
benzofuroxan) have been described as promising prototypes to design new compounds to treat 
cardiovascular disorders due to their antiplatelet activity [10–12] (Figure 1). Therefore, in a continuing 
effort to develop safe and effective antiplatelet and antithrombotic drug candidates, we report on the 
synthesis and pharmacological evaluation of new N-oxide derivatives that may prevent 
atherothrombotic events.  
 
Figure 1. Chemical structures of furoxan and benzofuroxan derivatives with antiplatelet 
activity [10–12].  
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2. Results and Discussion 
2.1. Chemistry 
The synthetic routes for preparing the intermediates (3a,b, 8a,b, 13a,b) and final compounds (4a,b, 
9a,b, 14a,b) are summarized in Scheme 1. The furoxan (2 and 6) and benzofuroxan (12) subunits were 
prepared according to previously described procedures [13,14]. The intermediates (3a,b, 8a,b, 13a,b) 
were prepared by condensation between aldehyde groups and various hydroxybenzhydrazides. These 
intermediates were obtained with variable yields of 75%–95% and the 1H-nuclear magnetic resonance 
(NMR) spectra of all intermediates showed one signal corresponding to the ylidenic hydrogen of the  
E-diastereomers [13,15].  
The final compounds (4a,b, 9a,b, 14a,b) were prepared in variable yields (21.6%–39.1%) through 
esterification between the carboxylic acid present in ASA and the hydroxyl group present in the 
intermediates (3a,b, 8a,b, 13a,b) using N,N′-dicyclohexylcarbodiimide as a coupling agent. All 
chemical structures were established by elemental analysis, infrared (IR) spectroscopy, and 1H- and  
13C-NMR. The purities of all compounds, as determined by high-performance liquid chromatography, 
were >98.5%.  
 
a) NaNO2, CH3COOH, 0 °C, 24 h, 38%; b) hydroxybenzhydrazide derivative, ethanol, acid catalysis, 25 °C, 
15 h, 38%–68%; c) DCC, dichloromethane, 25 °C, 15 h, 21.6%–39.1%; d) NaNO2, CH3COOH, 0 °C, 24 h, 
90%; e) Pyridinium chlorochromate, CH2Cl2, 25 °C, 24 h, 45%; f) NaN3, DMSO, 75 °C, 1 h, 99%; g) toluene, 
120 °C, 1.5 h, 78%. 
Scheme 1. Synthesis of furoxan (3a,b, 4a,b, 8a,b and 9a,b) and benzofuroxan derivatives 
(13a,b and 14a,b).  
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2.2. Pharmacological Evaluation 
2.2.1. Antiplatelet Activity and Nitric Oxide Release  
In vitro antiplatelet activity was evaluated using rat platelet-rich plasma in the presence of ADP  
(10 μM), arachidonic acid (100 μM) and collagen (5 μg/mL) [15,16]. Table 1 shows that all 
compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) at 150 μM inhibit platelet aggregation induced 
by all those agonists used. Antiplatelet activity induced by ADP ranged from 9.2% to 75.6% and 
activity induced by arachidonic acid ranged from 31.6% to 87.5%. For collagen, the antiplatelet 
inhibition ranged from 8.8% to 85.3%. All synthesized compounds demonstrated antiplatelet activity 
against ADP-induced platelet aggregation, whereas the parental drug (ASA) did not inhibit this pathway.  
Table 1. Antiplatelet activity (%) and NO release data of furoxan (3a,b, 4a,b, 8a,b and 
9a,b) and benzofuroxan derivatives (13a,b and 14a,b). 
Compounds 
Platelet Inhibition (%) a NO Release Data 
ADP (10 μM) Arachidonic Acid 
(100 μM) Collagen (5 μg/mL) 
%NO2− (mol/mol) b,  
50 × 10−4 M L-Cys 
Control c 0 0 0 0 
DNS N.D. d N.D. d N.D. d 10.5 ± 0.7 
ASA 0 72.2 ± 3.7 * 77.1 ± 3.7 * 0 
3a 10.1 ± 3.3 * 52.6 ± 4.1 * 17.5 ± 2.7 * 2.0 ± 0.7 
3b 16.8 ± 2.9 * 47.8 ± 3.7 * 10.5 ± 3.3 * 1.9 ± 1.1 
4a 65.6 ± 2.4 †,* 70.1 ± 2.9 * 37.8 ± 4.1 * 2.2 ± 0.4 
4b 75.6 ± 1.8 †,* 87.5 ± 2.6 †,* 34.5 ± 3.5 * 1.8 ± 1.7 
8a 12.4 ± 3.7 †,* 55.1 ± 4.3 * 21.8 ± 5.1 * 7.6 ± 1.2 
8b 9.2 ± 2.8 †,* 31.6 ± 3.9 * 8.8 ± 3.6 * 7.5 ± 0.9 
9a 53.4 ± 2.1 †,* 73.4 ± 3.3 * 43.5 ± 4.7 * 7.0 ± 0.8 
9b 68.8 ± 1.3 †,* 82.7 ± 2.1 †,* 47.2 ± 2.9 * 7.9 ± 1.3 
13a 47.1 ± 2.5 * 52.3 ± 3.8 * 45.1 ± 3.8 * 0 
13b 44.2 ± 5.1 †,* 57.8 ± 4.9  * 43.0 ± 3.1 * 0 
14a 74.9 ± 2.2 †,* 76.9 ± 3.1 * 85.3 ± 3.7 * 0 
14b 70.3 ± 1.7 †,* 79.1 ± 1.9 †,* 79.8 ± 3.4 * 0 
a Results are expressed as the mean for n = 3 independent experiments carried out in triplicate. All compounds 
and ASA were evaluated at 150 μM; b All values are the mean ± SEM. Determined by Griess reaction, after 
incubation for 1 h at 37 °C in pH 7.4 buffered water, in the presence of 1:50 molar excess of L-cysteine;  
c Vehicle DMSO (0.1% v/v) was used as a control; d N.D. not determined; * p < 0.01 versus the control group 
and † p < 0.01 versus ASA (ANOVA followed by Tukey test). 
Compounds 4b, 14a and 14b inhibited more than 70% of platelet aggregation induced by ADP. 
Interestingly, benzofuroxan derivatives (14a,b) showed antiplatelet activity superior to ASA in 
experiments using arachidonic acid and collagen as agonists. It was observed that benzofuroxan 
derivatives (14a,b) were more active as antiplatelet compounds than furoxan derivatives (4a,b, 9a,b). 
Furthermore, it was verified that those compounds containing the 2-acetoxybenzoyl subunit (4a,b, 9a,b, 
14a,b) had antiplatelet activity superior to their respective intermediates (3a,b, 8a,b, 13a,b) in the 
presence of all three agonists.  
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Nitrite quantification was used as an indirect method to evaluate the NO donor ability of all 
compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) in vitro [17]. The results of thiol-induced NO 
generation after incubation with a high concentration of L-cysteine (50 × 10−4 M) are shown in Table 1. 
Compounds induced nitrite formation at levels of 0%–7.9%. Isosorbide dinitrate (DNS), used as the 
control, induced nitrite formation at a level of 10.5%. Furoxan derivatives 3a,b and 4a,b demonstrated 
a similar ability to generate nitrite in medium. Such results were also observed for furoxan 8a,b and 9a,b. 
Benzofuroxan derivatives (13a,b and 14a,b) did not generate nitrite in the medium. In addition, it was 
characterized that the presence of the 2-acetoxybenzoyl subunit did not contribute to the release of NO 
in furoxan derivatives, suggesting that the antiplatelet effects of these compounds (3a,b, 4a,b, 8a,b, 
9a,b, 13a,b and 14a,b) could be independent of the NO action.  
2.2.2. In Vivo Antithrombotic Activity  
The antithrombotic effects of all compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) were 
evaluated in vivo using a mouse pulmonary thromboembolism model [18,19]. All compounds, after 
oral administration in a single dose, protected mice against thromboembolic events (Table 2).  
Table 2. In vivo antithrombotic effect of compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 
14a,b) and acetylsalicylic acid (ASA) using an acute pulmonary thromboembolism model 
induced by a collagen-epinephrine mixture. 
Compounds Paralyzed a or Died Animals/Total % Protection 
Control 9/10 10  
ASA 7/10 30 * 
3a 6/10 40 * 
3b 7/10 30 * 
4a 6/10 40 * 
4b 5/10 50 *,† 
8a 6/10 40 * 
8b 6/10 40 * 
9a 7/10 30 * 
9b 5/10 50 *,† 
13a 3/10 70 *,† 
13b 3/10 70 *,† 
14a 2/10 80 *,† 
14b 3/10 70 *,† 
The test compounds were orally administered at a dose of 100 µmol/10 g body weight (0.1 mL/10 g body 
weight). The χ2 test was used to compare the survival rate between the control and treated groups. * p < 0.05 
compared with the control group and † p < 0.05 compared with ASA. a The loss of the righting reflex was 
considered to indicate paralysis. 
The antithrombotic activities of 4b, 9b, 13a,b, and 14a,b were superior to that of ASA, used as a 
control. The benzofuroxan derivatives (13a,b and 14a,b) were the most effective compounds, 
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providing a survival of up to 80%. It was observed that compounds containing the 2-acetoxybenzoyl 
subunit (4b, 9b, and 14a) were more active than their intermediates (3b, 8b, and 13a). 
2.2.3. In Silico Studies 
Benzofuroxan derivatives have been described as inhibitors of cyclooxygenase (COX) enzymes, 
mainly for the isoform COX-1 [20]. Therefore, the ability of the benzofuroxan derivative (14a) to 
interact with COX-1 (PDB ID: 3KK6) and its mode of binding were investigated through docking 
studies using software Maestro v9.1 (Schrödinger®, New York, NY, USA). Figure 2 shows the main 
interactions of 14a with amino acid residues present in the active site of COX-1. The orientation of 
benzofuroxan 14a showed that the N-oxide subunit interacts through hydrogen bonding with His90 and 
Ser516 (3.1 Å). The amidic hydrogen of the N-acylhydrazone subunit interacts with residue Tyr355 
(3.3 Å). Furthermore, several hydrophobic interactions [21] were characterized between 14a and 
hydrophobic residues in the active site such as Leu531, Trp387, and Phe518 (less than 4.5 Å). This 
result could explain, in part, the antiplatelet effect observed for this compound; however, additional 
mechanisms need to be further investigated. 
 
Figure 2. Docking study of 14a (yellow colored carbon atoms) in the active site of COX-1 
(3KK6, residues labeled in gray for carbon). The hydrogen bond between N-oxide 
hydrogen and His90 and Ser516 (3.1 Å) residues is depicted by the dashed cyan line. The 
figure was generated using Pymol software (version 1.7.6). 
The in silico physico-chemistry and pharmacokinetic properties of 14a were determined using the 
pkCSM database [22]. Table 3 shows that 14a does not violate Lipinski’s rule of five and has an 
adequate pharmacokinetic profile for oral administration [23].  
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Table 3. Physico-chemistry properties and ADMET profile of 14a using pkCSM  
database [22].  
Predicted properties 14a 
Physico-chemistry properties 
Molecular weight: 460.1  
H donors: 1  
H acceptors: 9  
LogP: 2.36  
Number of rotatable bonds: 9  
Surface area: 191.27 
Absorption 
Water solubility: −4.71 log mol/L  
Caco2 permeability: −0.008 log Papp in 10−6 cm/s  
Intestinal absorption (humans): 86.54% absorbed  
Distribution VDss (humans): −0.869 log L/Kg 
Metabolism Substrate of CYP3A4 
Excretion Total clearance: 0.386 log mL/min/Kg 
Toxicity 
AMES toxicity: No  
hERG I inhibitor: No 
2.2.4. In Vivo Genotoxicity Studies 
The genotoxicity induced by 14a was evaluated using the micronucleus test [24]. Compound 14a 
was selected for the genotoxicity studies because N-oxide compounds, especially those containing the 
benzofuroxan subunit, have been associated with mutagenicity and genotoxicity [25,26]. 
Cyclophosphamide, used as positive control, induced a mean of 41 ± 5 micronucleated reticulocytes 
(MNRET) (Figure 3), whereas 14a was not able to cause genotoxicity (MNRET < 4). For 14a, 
MNRET values were similar to those present in the vehicle (CMC/Tween; negative control).  
 
Figure 3. Mean ± SD frequency of MNRET in 1000 cells obtained from mice treated with 
cyclophosphamide (50 mg/kg, positive control), CMC/Tween (negative control), and 
compound 14a (250 mg/kg). * p < 0.05 (compared with the positive control; ANOVA 
followed by Tukey test). 
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3. Experimental Section  
3.1. General 
The progress of all reactions was monitored by TLC, which was performed on 2.0 × 6.0 cm2 
aluminum sheets pre coated with silica gel 60 (HF-254, Merck, Kenilworth, NJ, USA) to a thickness of 
0.25 mm. The developed chromatograms were viewed under UV light (254 nm and 365 nm). Merck 
silica gel (70–230 mesh) was used for preparative column chromatography. Melting points were 
measured with an electrothermal melting-point apparatus (SMP3, Bibby Stuart Scientific, Stone, 
Staffordshire, UK) in open capillary tubes. Infrared spectra (KBr disc) were produced on an  
FTIR-8300 Shimadzu (Kyoto, Japan). 1H-NMR and 13C-NMR spectra were scanned on a Bruker 
DRX-400 (300 MHz) NMR spectrometer (Billerica, MA, USA) using DMSO-d6 as the solvent. The 
coupling constants are reported in hertz (Hz) and signal multiplicities are reported as singlet (s), 
doublet (d), doublet of doublet (dd), multiplet (m). Mass spectrometry of all compounds was obtained 
in positive mode using a model micrOTOF electrospray ionization-time of flight (ESI-TOF) (Bruker 
Daltonics, Billerica, MA, USA) spectrometer (conditions: injection at a flow rate of 300 L/h, capillary 
voltage of 4.5 kV, cone voltage of 120 V, desolvation temperature at 180 °C). Elemental analyses (C, 
H, and N) were performed on a Perkin Elmer model 240C analyzer (Waltham, MA, USA) and the data 
were within ±0.4% of the theoretical values. HPLC analysis was performed on a Shimadzu LC-10AD 
chromatograph equipped with a model SPD-10A UV-Vis detector (Shimadzu, Kyoto, Japan). The 
compounds were separated on a reversed phase C18 column (5 μm particle, 250 mm × 4.6 mm I.D.) 
Shimadzu Shim-pack CLC-ODS (M). HPLC-grade solvents (acetonitrile, methanol, and acetic acid) 
were used in the analyses and were bought from a local supplier. Reagents and solvents were 
purchased from commercial suppliers and used as received. The compounds aldehydes (3a), (3b), and 
(4) were prepared according methods previously described [13,14,27].  
3.2. Chemistry 
3.2.1. General Procedures for the Preparation of Intermediates (3a,b, 8a,b and 13a,b)  
The corresponding aromatic aldehyde (2, 7, or 12) (2 mmol) was added to a solution of previously 
selected 3- or 4-hydroxybenzhydrazide derivatives (2 mmol) in 15 mL of absolute ethanol, in the 
presence of a catalytic amount of 37% hydrochloric acid (80 µL). The reaction was stirred for 15 h at 
room temperature and monitored by TLC. Afterwards, the solvent was partially concentrated at 
reduced pressure, and the resulting mixture was poured into cold water. The precipitate was collected 
by filtration, washed with cold ethanol, and dried under vacuum to give the intermediates containing 
the N-acyl hydrazone subunit (3a,b, 8a,b and 13a,b). If necessary, the compounds can be purified by 
column chromatography (flash silica, eluent: 70% ethyl acetate; 30% hexane).  
3-((2-(3-Hydroxybenzoyl)hydrazono)methyl)-4-methyl-1,2,5-oxadiazole 2-oxide (3a): Pale yellow solid. 
Yield: 47.2%, mp: 225–227 °C. IR νmax (cm−1; KBr pellets): 3414 (O-H), 1635 (C=O amide), 1616 
(C=N), 1458 (C-H methyl), 1300 (N-O) and 800 (C-H aromatic). 1H-NMR (300 MHz, DMSO-d6) δ: 
9.80 (1H; O-H), 8.46 (1H; s; C-Himine), 7.36 (1H; t; J = 7.9 Hz; C-Haromatic), 7.34 (1H; t; J = 7.9 Hz;  
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C-Haromatic), 7.31 (1H; t; J = 7.9 Hz; C-Haromatic), 7.01 (1H; d; C-Haromatic), 7 (1H; N-Hamide), 2.39 (3H; s; 
C-Hmethyl) ppm. 13C-NMR (75 MHz, DMSO-d6) δ: 137.7, 129.5, 119.2, 118.1, 114.7, 9.0 ppm. 
Analysis calculated for C11H10N4O4: C, 50.38; H, 3.84; N, 21.37. Found: C, 50.11; H, 3.82; N, 21.21. 
Mass calculated: m/z 262.07; Found Low-resolution mass spectrometry (LRMS): m/z 263.07 [M + H]+. 
3-((2-(4-Hydroxybenzoyl)hydrazono)methyl)-4-methyl-1,2,5-oxadiazole 2-oxide (3b): Pale yellow solid. 
Yield: 48.35%, mp: 250–253 °C. IR νmax (cm−1; KBr pellets): 3316 (O-H), 2922 (C-H aromatic), 
1617 (C=O amide), 1507 (N=O) and 1277 (C-H methyl). 1H-NMR (300 MHz, DMSO-d6) δ: 9.60 (1H; 
O-H), 8.49 (1H; s; C-Himine), 7.67 (2H; dd; J = 7.6 Hz; C-Haromatic), 6.72 (2H; dd; J = 7.6 Hz; C-
Haromatic), 4.46 (1H; N-Hamide), 2.08 (3H; s; C-Hmethyl) ppm. 13C-NMR (75 MHz, DMSO-d6) δ: 166, 160, 
128, 124, 114, 71.6, 69.6, 26.5 ppm. Analysis calculated for C11H10N4O4: C, 50.38; H, 3.84; N, 21.37. 
Found: C, 50.3; H, 3.81; N, 21.5. Mass calculated: m/z 262.07; Found LRMS: m/z 263.07 [M + H]+. 
3-((2-(3-Hydroxybenzoyl)hydrazono)methyl)-4-phenyl-1,2,5-oxadiazole 2-oxide (8a): White solid. 
Yield: 39.1%, mp: 236.1–237.5 °C. IR νmax (cm−1; KBr pellets): 3412 (O-H), 1653 (C=O amide), 
1616 (C=N), 1400 (N=O), 1303 (N-O), 833 (C-H aromatic) and 744 (C-H aromatic). 1H-NMR (300 MHz, 
DMSO-d6) δ: 9.84 (1H; O-H), 8.37 (1H; s; C-Himine), 7.98 (2H; d; J = 8.1 Hz; C-Haromatic), 7.67 (1H; d; 
C-Haromatic), 7.61 (2H; d; J = 8.1 Hz; C-Haromatic), 7.58 (1H; C-Haromatic), 7.31 (2H; d; C-Haromatic), 7.28 
(1H; d; C-Haromatic), 7.01 (1H; s; C-Haromatic) ppm. 13C-NMR (75 MHz, DMSO-d6) δ: 157.3, 155.9, 
133.7, 131.1, 129.5, 128.9, 128.6, 125.5, 119.0, 118.1, 114.4 ppm. Analysis calculated for C16H12N4O4: 
C, 59.26; H, 3.73; N, 17.28. Found: C, 59.1; H, 3.69; N, 17.44. Mass calculated: m/z 324.09; Found 
LRMS: m/z 325.09 [M + H]+. 
3-((2-(4-Hydroxybenzoyl)hydrazono)methyl)-4-phenyl-1,2,5-oxadiazole 2-oxide (8b): White solid. 
Yield: 38.5%, mp: 221–222.3 °C. IR νmax (cm−1; KBr pellets): 3412 (O-H), 1635 (C=O amide), 1616 
(C=N), 1400 (N=O), 1294 (N-O) and 684 (C-H aromatic). 1H-NMR (300 MHz, DMSO-d6) δ: 10.24 
(1H; O-H), 8.32 (1H; s; C-Himine), 7.96 (2H; d; J = 8 Hz; C-Haromatic), 7.79 (2H; dd; C-Haromatic), 7.60 
(2H; d; J = 8 Hz; C-Haromatic), 7.56 (1H; C-Haromatic), 6.85 (2H; dd; C-Haromatic) ppm. 13C-NMR (75 MHz, 
DMSO-d6) δ: 166.1, 161.0, 156.7, 155.8, 151.2, 132.7, 131.3, 129.5, 128.3, 127.9, 124.0, 116.5, 118.4, 
113.7 ppm. Analysis calculated for C16H12N4O4: C, 59.26; H, 3.73; N, 17.28. Found: C, 58.98; H, 3.75; 
N, 17.52. Mass calculated: m/z 324.09; Found LRMS: m/z 325.09 [M + H]+. 
5-((2-(3-Hydroxybenzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (13a): Mustard yellow 
solid. Yield: 50.9%, mp: 263.2–264 °C. IR νmax (cm−1; KBr pellets): 3431 (O-H), 1654 (C=O amide), 
1616 (C=N), 1400 (N=O), 1298 (N-O), 794 (C-H aromatic) and 745 (C-H aromatic). NMR 1H (300 MHz, 
DMSO-d6) δ: 9.80 (1H; O-H), 8.46 (1H; s; C-Himine), 8.01 (1H; C-Haromatic), 7.88 (1H; C-Haromatic), 7.87 
(1H; C-Haromatic), 7.36 (1H; d; J = 7.6 Hz; C-Haromatic), 7.34 (1H; dd; J = 7.6 Hz; C-Haromatic), 7.31 (1H; 
m; C-Haromatic), 7.01 (1H; dd; C-Haromatic), 4.69 (1H; N-Hamide) ppm. 13C-NMR (75 MHz, DMSO-d6) δ: 
145.0, 130.7, 129.6, 119.0, 118.6, 118.1, 114.5, 113.2 ppm. Analysis calculated for C14H10N4O4: C, 
56.38; H, 3.38; N, 18.78. Found: C, 56.05; H, 3.13; N, 19.04. Mass calculated: m/z 298.07; Found 
LRMS: m/z 299.07 [M + H]+. 
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5-((2-(4-Hydroxybenzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (13b): Yellow solid. 
Yield: 68%, mp: 295–297 °C. IR νmax (cm−1; KBr pellets): 3336 (O-H), 3081 (C-H aromatic), 1654 
(C=O amide), 1607 (C=N), 1507 (N=O) and 795 (C-H aromatic). 1H-NMR (300 MHz, DMSO-d6) δ: 
10.28 (1H; O-H), 8.45 (1H; s; C-Himine), 7.83 (2H; dd; J = 8.2 Hz; C-Haromatic), 6.88 (2H; dd; J = 8.2 Hz; 
C-Haromatic) ppm. 13C-NMR (75 MHz, DMSO-d6) δ: 164.6, 143.0, 130.3, 128.6, 124.0, 114.8 ppm. 
Analysis calculated for C14H10N4O4: C, 56.38; H, 3.38; N, 18.78. Found: C, 56.42; H, 3.63; N, 18.55. 
Mass calculated: m/z 298.07; Found LRMS: m/z 299.07 [M + H]+. 
3.2.2. General Procedures for the Preparation of Compounds (4a,b, 9a,b, and 14a,b) 
A mixture of N-acylhydrazone derivatives (3a,b, 8a,b and 13a,b) (1.15 mmol), acetylsalicylic acid 
(1 mmol) (1.0 mmol), dicyclohexylcarbodiimide (1.0 mmol), dimethylaminopyridine (0.1 mmol), and 
20 mL of anhydrous dichloromethane was stirred under nitrogen at 0 °C for 15 h. Subsequently the 
mixture was filtered and the solvent was evaporated at reduced pressure. The compounds were purified 
by silica gel column chromatography, using ethyl acetate:hexane (70:30) at the mobile phase to give 
the compounds variable yields (21.6%−39.1%). 
(E)-3-((2-(3-((2-Acetoxybenzoyl)oxy)benzoyl)hydrazono)methyl)-4-methyl-1,2,5-oxadiazole 2-oxide (4a): 
Pale yellow solid. Yield: 23.07%, mp: 132–135.4 °C. IR νmax (cm−1; KBr pellets): 3431 (N-H), 1697 
(C=O ester), 1643 (C=O amide), 1616 (C=N), 1462 (C-H methyl) and 1157 (C-O ester). 1H-NMR  
(300 MHz, DMSO-d6) δ: 8.49 (1H; s; C-Himine), 8.03 (1H; dd; C-Haromatic), 8.00 (1H; s; C-Haromatic), 
7.93 (1H; C-Haromatic), 7.90 (1H; C-Haromatic), 7.86 (1H; t; J = 7.8 Hz; C-Haromatic), 7.66 (1H; d; C-Haromatic), 
7.63 (1H; t; J = 7.8 Hz; C-Haromatic), 7.60 (1H; d; C-Haromatic), 7.05 (1H; N-H), 2.41 (3H; s; C-H3furoxan), 
2.01 (3H; s; COCH3) ppm. 13C-NMR (75 MHz, DMSO-d6) δ: 136.0, 135.0, 130.6, 129.8, 129.7, 126.0, 
125.4, 121.2, 115.0, 20.3, 8.77 ppm. Analysis calculated for C20H16N4O7: C, 56.61; H, 3.80; N, 13.20. 
Found: C, 56.28; H, 3.66; N, 13.57. Mass calculated: m/z 424.10; Found LRMS: m/z 425.10 [M + H]+. 
(E)-3-((2-(4-((2-Acetoxybenzoyl)oxy)benzoyl)hydrazono)methyl)-4-methyl-1,2,5-oxadiazole 2-oxide (4b): 
Pale yellow solid. Yield: 26.44%, mp: 179.3–180 °C. IR νmax (cm−1; KBr pellets): 3441 (N-H), 1747 
(C=O ester), 1639 (C=O amida), 1616 (C=N), 1458 (C-H methyl), 1168 (C-O ester). 1H-NMR (300 MHz, 
DMSO-d6) δ: 8.47 (1H; s; C-Himine), 8.20 (1H; dd; J = 8.1 Hz; C-Haromatic), 7.96 (1H; t; C-Haromatic), 
7.81 (2H; dd; J = 8.1 Hz; C-Haromatic), 7.53 (1H; d; C-Haromatic), 7.36 (1H; t; C-Haromatic), 6.87 (2H; dd;  
C-Haromatic), 2.44 (3H; s; C-H3furoxan), 2.28 (3H; s; COCH3) ppm. 13C-NMR (75 MHz, DMSO-d6) δ: 
135.0, 131.4, 129.8, 129.0, 126.7, 121.6, 115.0, 20.9, 9.0 ppm. Analysis calculated for C20H16N4O7: C, 
56.61; H, 3.80; N, 13.20. Found: C, 56.87; H, 4.03; N, 13.38. Mass calculated: m/z 424.10; Found 
LRMS: m/z 425.10 [M + H]+. 
(E)-3-((2-(3-((2-Acetoxybenzoyl)oxy)benzoyl)hydrazono)methyl)-4-phenyl-1,2,5-oxadiazole 2-oxide (9a): 
Yellow solid. Yield: 39.09%, mp: 119.1–122.7 °C. IR νmax (cm−1; KBr pellets): 3431 (N-H), 1743 
(C=O ester), 1650 (C=O amide), 1616 (C=N), 1452 (C-H methyl), 1203 (C-O ester) and 693 (C-H 
aromatic). 1H-NMR (300 MHz, DMSO-d6) δ: 8.37 (1H; s; C-Himine), 8.20 (1H; dd; C-Haromatic), 7.97 
(2H; d; J = 7.8 Hz; C-Haromatic), 7.88 (1H; d; C-Haromatic), 7.81 (1H; C-Haromatic), 7.80 (1H; d; C-Haromatic), 
7.78 (1H; d; C-Haromatic), 7.65 (1H; d; J = 7.8 Hz; C-Haromatic), 7.62 (1H; t; C-Haromatic), 7.58 (2H; d;  
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C-Haromatic), 7.52 (1H; s; C-Haromatic), 7.34 (1H; d; C-Haromatic), 2.28 (3H; s; C-Hmethyl) ppm. 13C-NMR 
(75 MHz, DMSO-d6) δ: 135.0, 133.0, 131.4, 131.0, 128.8, 128.5, 125.2, 125.1, 124.7, 124.0, 121.0, 
120.7, 20.8 ppm. Analysis calculated for C25H18N4O7: C, 61.73; H, 3.73; N, 11.52. Found: C, 61.56; H, 
3.91; N, 11.77. Mass calculated: m/z 486.12; Found LRMS: m/z 487.12 [M + H]+. 
(E)-3-((2-(4-((2-Acetoxybenzoyl)oxy)benzoyl)hydrazono)methyl)-4-phenyl-1,2,5-oxadiazole 2-oxide (9b): 
Yellow solid. Yield: 38.46%, mp: 139.6–141.1 °C. IR νmax (cm−1; KBr pellets): 3421 (N-H), 1751 
(C=O ester), 1639 (C=O amide), 1616 (C=N), 1458 (C-H methyl), 1195 (C-O ester) and 692 (C-H 
aromatic). 1H-NMR (300 MHz, DMSO-d6) δ: 8.36 (1H; s; C-Himine), 8.20 (1H; t; C-Haromatic), 7.96 (2H; 
d; J = 7.9 Hz; C-Haromatic), 7.80 (2H; dd; C-Haromatic), 7.62 (1H; dd; C-Haromatic), 7.60 (2H; d; J = 7.9 Hz; 
C-Haromatic), 7.51 (1H; s; C-Haromatic), 7.42 (1H; d; C-Haromatic), 7.35 (2H; dd; C-Haromatic), 7.32 (1H; d; 
C-Haromatic),  2.30 (3H; s; C-Hmethyl) ppm. 13C-NMR (75 MHz, DMSO-d6) δ: 135.1, 133.0, 131.8, 131.0, 
129.0, 128.7, 126.4, 124.0, 122.0, 21.0 ppm. Analysis calculated for C25H18N4O7: C, 61.73; H, 3.73;  
N, 11.52. Found: C, 61.92; H, 3.91; N, 11.8. Mass calculated: m/z 486.12; Found LRMS: m/z 487.12 
[M + H]+. 
(E)-5-((2-(3-((2-Acetoxybenzoyl)oxy)benzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (14a): 
Yellow solid. Yield: 21.6%, mp: 182–184.5 °C. IR νmax (cm−1; KBr pellets): 3414 (N-H), 1747 (C=O 
ester), 1635 (C=O amide), 1616 (C=N), 1400 (C-H methyl) and 1298 (N-O). 1H-NMR (300 MHz, 
DMSO-d6) δ: 8.51 (1H; s; C-Himine), 8.00 (1H; J = 7.7 Hz; C-Haromatic), 7.85 (1H; J = 7.7 Hz; C-Haromatic), 
7.83 (1H; t; C-Haromatic), 7.69 (1H; t; C-Haromatic), 7.60 (1H; J = 7.7 Hz; C-Haromatic), 7.58 (1H; m; C-Haromatic), 
7.40 (1H; t; C-Haromatic) 5.51 (1H; N-H), 2.31 (3H; s; C-Hmethyl) ppm. 13C-NMR (75 MHz, DMSO-d6)  
δ: 146.0, 131.2, 130.0, 126.1, 126.0, 125.5, 121.4, 119.6, 21.2 ppm. Analysis calculated for 
C23H16N4O7: C, 60.00; H, 3.50; N, 12.17. Found: C, 60.29; H, 3.19; N, 12.41. Mass calculated: m/z 
460.10; Found LRMS: m/z 461.10 [M + H]+. 
(E)-5-((2-(4-((2-Acetoxybenzoyl)oxy)benzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (14b): 
Yellow solid. Yield: 22.68%, mp: 197–200 °C. IR νmax (cm−1; KBr pellets): 3419 (N-H), 1751 (C=O 
ester), 1653 (C=O amide), 1620 (C=N), 1400 (C-H methyl), 1202 (C-O ester) and 640 (C-H aromatic). 
1H-NMR (300 MHz, DMSO-d6) δ: 8.50 (1H; s; C-Himine), 8 (1H; C-Haromatic), 7.98 (2H; dd; J = 8 Hz;  
C-Haromatic), 7.89 (1H; C-Haromatic), 7.33 (2H; dd; J = 8 Hz; C-Haromatic), 5.54 (1H; N-H), 2.32 (3H; s;  
C-Hmethyl) ppm. 13C-NMR (75 MHz, DMSO-d6) δ: 145.0, 131.1, 130.4, 129.9, 129.4, 121.6, 21.0 ppm. 
Analysis calculated for C23H16N4O7: C, 60.00; H, 3.50; N, 12.17. Found: C, 60.35; H, 3.66; N, 12.38. 
Mass calculated: m/z 460.10; Found LRMS: m/z 461.10 [M + H]+. 
3.3. Pharmacology 
3.3.1. Animals 
Adult male Swiss albino mice (20−35 g) and Wistar rats (200–250 g) were used in the experiments. 
They were housed in single-sex cages under a 12 h light:12 h dark cycle in a controlled-temperature 
room (22 ± 2 °C). The animals had free access to food and water. The experiments were performed 
after the protocol was approved by The Research Ethics Committee of the School of Pharmaceutical 
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Sciences, UNESP, Araraquara (CEP/FCFAR/2011). All experiments were performed in accordance 
with the current guidelines for the care of laboratory animals and the ethical guidelines for the 
investigation of experimental pain in conscious animals. 
3.3.2. Antiplatelet Activity 
Five rats (Wistar; 200–250 g) were previously anesthetized by inhalation of isoflurane using a 
vaporizing system. Animal breathing was monitored during all procedures. Blood was withdrawn from 
each rat’s aorta artery and mixed with 3.8% trisodium citrate (9:1 v/v). The animals were then 
euthanized by deepening of anesthesia. Platelet-rich plasma (PRP) was prepared by centrifugation 
at 375× g for 10 min at room temperature. The platelet-poor plasma (PPP) was prepared by 
centrifugation of the pellet at 1800× g for 10 min at room temperature. Platelet aggregation was 
monitored by the turbidimetric method of Born and Cross [16] using a Chrono-Log aggregometer. PRP 
(300 μL) was incubated at 37 oC for 1 min with continuous stirring at 900 rpm. ADP (10 μM), type I 
collagen (5 μg/mL; molecular weight of 115–130 kDa) and arachidonic acid (100 μM) were used to 
induce platelet aggregation. All compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) at 150 μM or 
vehicle DMSO (0.5% v/v) were added to the PRP samples 1 min before addition of the aggregating 
agent (ADP, 10 μM; collagen, μg/mL; or arachidonic acid, 100 μM). Acetylsalicylic acid (AAS,  
150 μM) was used as positive control. The results were expressed as an inhibition percentage. The 
statistical analysis was performed using ANOVA followed by Tukey’s test. 
3.3.3. In vitro Nitric Oxide Production 
Test compounds, previously solubilized in DMSO (20 μL), were added to a 2 mL solution (50 mM 
phosphate buffer (pH 7.4)/methanol (1:1, v/v)) containing 5 mM L-cysteine. For all test compounds the 
final concentration was 10−4 M. This mixture was incubated for 1 h at 37 °C. After incubation,  
250 μL of Griess reagent was added to 1 mL of this mixture. The absorbance was measured at 540 nm 
using a Shimadzu UV-2501PC spectrophotometer (Kyoto, Japan). A calibration curve of standard 
sodium nitrite was used to quantify the % NO2 in the medium [17,27].  
3.3.4. In vivo Antithrombotic Activity  
In vivo pulmonary thromboembolism was induced in mice according to previously described 
procedures [18,19]. Ten Swiss male mice (25−30 g) were used in each test group and the control 
group. Compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) and acetylsalicylic acid were given orally  
(100 µmol/10 g, 0.1 mL/10 g) using a 2% carboxymethylcellulose suspension as the vehicle. After 60 min, 
an intravenous injection of the thrombogenic stimulus containing a mixture of collagen (11 mg/kg) 
plus epinephrine (0.7 mg/kg) was administered through the tail vein. The dose of the pro-thrombotic 
mixture was previously characterized using a dose/response curve able to reliably reproduce 80%–90% 
mortality rate or animal paralysis [15]. The loss of the righting reflex was considered an indication of 
animal’s paralysis in the control group. The rates of animal survival and paralysis were evaluated 15 
min after the administration of the thrombogenic stimulus. After this time, the animals were euthanized 
using carbon dioxide. In the control group, there were five deaths. For ASA and 3a, 3b, 4a, 8a, 8b, and 
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9a, there were two deaths per group. The protection against acute pulmonary thromboembolism 
(percentage) was calculated as follows: [1 − (paralyzed + death animals)/total animals] × 100. The  
chi-square test was used to examine the difference between the control and treated groups. 
3.3.5. In Silico Studies 
Molecular modeling studies were performed with Maestro software Maestro v9.1, software 
available from Schrödinger Inc, New York, NY, USA [28]. The ligand-bound crystallographic 
structure of cyclooxygenase (COX-1) is available in the Protein Data Bank. In this study, celecoxib 
crystalized in the active site of COX-1 (pdb code: 3KK6) was selected for docking studies [29]. The 
crystallographic water molecules, ions and cofactors were deleted, hydrogen atoms were added, and 
formal charges along with bond orders were assigned to the structure. The ligand (14a) was prepared 
using LigPrep (Schrödinger) [30]. Using OPLS 2005 force field, 32 stereochemical structures per ligand 
were generated. The grid was generated as a cubic box of 10 Å × 10 Å × 10 Å centered on the active 
site residues. The SP flexible ligand docking was performed using Glide within Schrödinger-Maestro 
v9.1 [31]. The final score was obtained for energy-minimized poses and the best-docked pose with 
lowest glide score was selected for 14a. In silico physico-chemistry and pharmacokinetic properties 
were determined using the pkCSM database [22]. 
3.3.6. In Vivo Genotoxicity Study  
Compound 14a (250 mg/kg) and negative control (1% carboxymethylcellulose (CMC) suspension 
and 0.2% tween; 0.3 mL) were administered to the animals orally. The positive control group received 
cyclophosphamide (50 mg/kg; i.p.). Groups of 10 Swiss mice of both sexes (25−30 g) were used in 
each test and control group. After 30 h, the animals were anesthetized using a mixture of 
ketamine/xylazine (100/10 mg/kg; i.p.), and 0.5 mL of blood were collected from the tail vein and 
added to laminas pre-stained with acridine orange. The animals were euthanized via deepening of 
anesthesia. One thousand reticulocytes per animal were counted, and the frequency of micronucleated 
cells was registered. These results were tested with analysis of variance (ANOVA). When p < 0.05, the 
average values for the treatments were compared using the Tukey method, calculating the minimum 
significant difference at α = 0.05. 
4. Conclusions 
In this study, we synthesized and characterized a series of furoxan and benzofuroxan derivatives (3a,b, 
4a,b, 8a,b, 9a,b, 13a,b, and 14a,b). All compounds demonstrated antiplatelet activity induced by 
ADP, collagen and arachidonic acid. The furoxan derivatives (3a,b, 4a,b, 8a,b, and 9a,b) released NO  
in vitro; however, this effect was not observed for benzofuroxan derivatives (13a,b and 14a,b). The 
presence of N-oxide in benzofuroxan derivatives seems to be relevant for hydrogen bond interactions 
with His90 and Ser516 in the active site of COX-1. Furthermore, benzofuroxan derivatives (13a,b and 
14a,b) were the most effective compounds in the pulmonary thromboembolism model induced by 
collagen and epinephrine, providing a survival rate up to 80%. Finally, the micronucleus test using 
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peripheral blood cells of mice showed that the benzofuroxan derivative 14a was non-genotoxic. Based 
on these results, 14a has emerged as a new prototype useful for the prevention of atherothrombotic events.  
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